Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges
The Senior Care Pharmacist · 01.04.2026 · 41 (3) · 98-108
DOI: 10.4140/tcp.n.2026.98 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Senior Care Pharmacist, erschienen am 01.04.2026. Verfasst von Muhammad A Qudoos und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1Ambulatory Care Pharmacy, Samaritan Lebanon Community Hospital, Lebanon, OR. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and functional impairment, primarily driven by the accumulation of amyloid-beta (Aβ) plaques and tau tangles. Historically, treatments have focused on symptomatic relief; however, recent therapeutic advances have focused on disease-modifying monoclonal antibodies (mAbs), notably lecanemab and donanemab, which target Aβ pathology in early-stage AD. This review explores the clinical efficacy, safety profile, and limitations of lecanemab and donanemab, emphasizing key findings from the CLARITY-AD and TRAILBLAZER-ALZ 2 trials. In these studies, lecanemab was shown to slow cognitive decline by 27% over 18 months, while donanemab achieved a 28.9% reduction over 76 weeks, with the greatest benefits observed in patients presenting with lower baseline tau pathology.Despite these promising outcomes, challenges remain, including possible reduced efficacy in women based on subgroup analyses of trial data, racial disparities in trial representation, adverse effects such as amyloid-related imaging abnormalities (ARIA), and substantial cost and accessibility barriers. This review underscores the need for more inclusive research, personalized treatment strategies, and continued exploration of AD’s complex pathology beyond amyloid clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Ambulatory Care Pharmacy, Samaritan Lebanon Community Hospital, Lebanon, OR.
- 2West Virginia University School of Pharmacy, Charleston, WV.
Zitieren
APA
Qudoos, M. A., & Elliott, D. P. (2026). Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges. The Senior Care Pharmacist, 41(3), 98-108. https://doi.org/10.4140/tcp.n.2026.98
Vancouver
Qudoos MA, Elliott DP. Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges. The Senior Care Pharmacist. 2026;41(3):98-108. doi:10.4140/tcp.n.2026.98
BibTeX
@article{Qudoos2026,
author = {Qudoos, Muhammad A and Elliott, David P},
title = {Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges},
journal = {The Senior Care Pharmacist},
year = {2026},
volume = {41},
number = {3},
pages = {98--108},
doi = {10.4140/tcp.n.2026.98}
}
EUVIMED